Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Investigation

• Publication date

  2003-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1172/JCI17500PMID 12727925PMCID PMC154449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Effects of Vasoactive Intestinal Peptide on Monocrotaline Induced Pulmonary Hypertensive Rabbits following Cardiopulmonary Bypass: A Comparative Study with Isoproteronol and Nitroglycerine

  2002cited by this paper
• Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-&bgr;1 and Bone Morphogenetic Proteins

  2001cited by this paper
• Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

  2001cited by this paper
• Immunohistochemical and Immunochemical Evidence for Exprssion of Human Lung PACAP/VIP Receptors

  2000cited by this paper
• Prostacyclin Analogues Differentially Inhibit Growth of Distal and Proximal Human Pulmonary Artery Smooth Muscle Cells

  2000cited by this paper
• Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation.

  2000cited by this paper
• Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.

  2000cited by this paper
• Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung.

  2000cited by this paper
• Inhaled nitric oxide and nifedipine have similar effects on lung cGMP levels in rats.

  1999cited by this paper
• Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer.

  1998cited by this paper
• Vasoactive intestinal peptide causes nitric oxide-dependent pulmonary vasodilation in isolated rat lung.

  1997cited by this paper
• Lymphoid Cell Accumulation in Salivary Glands of Autoimmune MRL Mice Can be Due to Impaired Apoptosis

  1997cited by this paper
• Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension.

  1997cited by this paper
• A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

  1996cited by this paper
• Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

  1995cited by this paper
• VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells.

  1995cited by this paper
• Importance of vasoactive intestinal peptide and somatostatin for fluid losses in small-bowel obstruction.

  1995cited by this paper
• Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor.

  1994cited by this paper
• Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.

  1994cited by this paper
• Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

  1993cited by this paper
• Effect of vasoactive intestinal polypeptide (VIP) on pulmonary ventilation-perfusion relationships and central haemodynamics in healthy subjects.

  1993cited by this paper
• An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

  1992cited by this paper
• Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

  1992cited by this paper
• Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea.

  1991cited by this paper
• Cloning and expression of the human vasoactive intestinal peptide receptor.

  1991cited by this paper
• Ventilatory effects of substance P, vasoactive intestinal peptide, and nitroprusside in humans.

  1990cited by this paper
• Primary pulmonary hypertension

  1988cited by this paper
• PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY

  1987cited by this paper
• Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries.

  1987cited by this paper
• The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.

  1985cited by this paper
• VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF).

  1984cited by this paper
• The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans.

  1984cited by this paper
• Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma.

  1984cited by this paper
• An endogenous peptide stimulates secretory activity in the elasmobranch rectal gland.

  1983cited by this paper
• Psychophysical bases of perceived exertion.

  1982cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Blood Vessels

  1959cited by this paper
• THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS

  1949cited by this paper

• Encapsidic production and isolation of degradation-prone polypeptides

  2025cites this paper
• Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications

  2024cites this paper
• The role of vasoactive intestinal peptide in pulmonary diseases.

  2023cites this paper
• Emerging biologics for the treatment of pulmonary arterial hypertension

  2023cites this paper
• New Drugs and Therapies in Pulmonary Arterial Hypertension

  2023cites this paper
• Recent Developments in Drug Targets and Combination Therapy for the Clinical Management of Hypertension.

  2023cites this paper
• The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial*

  2022cites this paper
• Pathophysiology and Pathogenic Mechanisms of Pulmonary Hypertension: Role of Membrane Receptors, Ion Channels and Ca2+ Signaling.

  2022cites this paper
• Novel and emerging therapies in pulmonary arterial hypertension

  2022influential citation
• Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial

  2022cites this paper
• Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide

  2022cites this paper
• The role of exome sequencing in childhood interstitial or diffuse lung disease

  2022cites this paper
• Plasminogen-derived peptide promotes adipogenic differentiation of preadipocytes in vitro and in vivo

  2022cites this paper
• Novel Insights into the Therapeutic Potential of Lung-Targeted Gene Transfer in the Most Common Respiratory Diseases

  2022cites this paper
• Comprehensive Review on Novel Targets and Emerging Therapeutic Modalities for Pulmonary Arterial Hypertension.

  2022cites this paper
• PULMONER ARTERİYEL HİPERTANSİYON TEDAVİSİNDE GÜNCEL YAKLAŞIMLAR

  2021cites this paper
• Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension

  2021cites this paper
• Anticipated pharmacological role of Aviptadil on COVID-19

  2021cites this paper
• Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

  2021cites this paper
• Increased Recovery and Survival in Patients With COVID-19 Respiratory Failure Following Treatment with Aviptadil: Report #1 of the ZYESAMI COVID-19 Research Group

  2021cites this paper
• Pulmonary Arterial Hypertension

  2021cites this paper
• VIP/PACAP signaling as an alternative target during hyperoxic exposure in preterm newborns.

  2021cites this paper
• Peptide Blocking Self-Polymerization of Extracellular Calcium-Sensing Receptor Attenuates Hypoxia-Induced Pulmonary Hypertension

  2021cites this paper
• Potassium (K+) channels in the pulmonary vasculature: Implications in pulmonary hypertension Physiological, pathophysiological and pharmacological regulation.

  2021cites this paper
• A strange case of severe but fleeting hypoxemia in patient with COVID-19 infection: maybe virus-induced pulmonary Raynaud's phenomenon?

  2021cites this paper
• REQUEST FOR BREAKTHROUGH THERAPY DESIGNATION Treatment of patients with Critical COVID-19 who are at immediate risk of death from Respiratory Failure despite treatment with approved therapy including remdesivir

  2021cites this paper
• Novel β-Coronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments

  2020cites this paper
• Rapid Recovery from COVID-19 Respiratory Failure after treatment with Vasoactive Intestinal Peptide

  2020cites this paper
• Current pharmacological treatments for COVID‐19: What's next?

  2020cites this paper
• Vasoactive Intestinal Peptide treats Respiratory Failure in COVID-19 by rescuing the Alveolar Type II cell

  2020cites this paper
• Pulmonary arterial hypertension specific therapy: The old and the new.

  2020cites this paper
• Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide

  2020cites this paper
• Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.

  2020cites this paper
• Rapid Recovery from Critical COVID-19 Respiratory Failure after treatment with VIP

  2020cites this paper
• A novel peptide relieves endothelial cell dysfunction in preeclampsia by regulating the PI3K/mTOR/HIF1α pathway

  2020cites this paper
• Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

  2020cites this paper
• Vasoactive Intestinal Peptide Is Potentially Lifesaving in Treating COVID-19

  2020cites this paper
• Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension

  2020cites this paper
• Cys-peptide mediates the protective role in preeclampsia-like rat and cell models.

  2020cites this paper
• Natriuretic peptides as the basis of peptide drug discovery for cardiovascular diseases.

  2020cites this paper
• Pulmonale Hypertonie

  2019cites this paper
• A novel peptide suppresses adipogenic differentiation through activation of the AMPK pathway.

  2019cites this paper
• Vasoactive intestinal peptide‐induced tolerogenic dendritic cells attenuated arthritis in experimental collagen‐induced arthritic mice

  2019cites this paper
• Pulmonary arterial hypertension: the case for a bioelectronic treatment

  2019cites this paper
• A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases

  2019cites this paper
• The Search for Disease-Modifying Therapies in Pulmonary Hypertension

  2019cites this paper
• Recent advances in pulmonary arterial hypertension

  2018cites this paper
• Protein Nanoparticles: Promising Platforms for Drug Delivery Applications.

  2018cites this paper
• Respirable powder formulation of a shortened vasoactive intestinal peptide analog for treatment of airway inflammatory diseases

  2018cites this paper
• HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes

  2018cites this paper
• Emerging therapeutics in pulmonary hypertension.

  2018cites this paper
• GPCRs in pulmonary arterial hypertension: tipping the balance

  2018cites this paper
• Genetic Disruption of VIP Signaling Alters Intestinal Microbial Structure and Immunity

  2018cites this paper
• VIP Regulates Morphology and F-Actin Distribution of Schlemm's Canal in a Chronic Intraocular Pressure Hypertension Model via the VPAC2 Receptor.

  2018cites this paper
• NFATc 3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease

  2018cites this paper
• Glaucoma VIP Regulates Morphology and F-Actin Distribution of Schlemm ’ s Canal in a Chronic Intraocular Pressure Hypertension Model via the VPAC 2 Receptor

  2018cites this paper
• Analyse de la valeur pronostique de l’expression immunohistochimique de VIPR2 dans une série rétrospective de 59 léïomyosarcomes utérins

  2018cites this paper
• Principles of pharmacological correction of pulmonary arterial hypertension

  2018cites this paper
• Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes

  2017cites this paper
• Novel strategies for treatment of pulmonary arterial hypertension.

  2017cites this paper
• NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease

  2017cites this paper
• Effect of Red Light-Emitting Diodes Irradiation on Hemoglobin for Potential Hypertension Treatment Based on Confocal Micro-Raman Spectroscopy

  2017cites this paper
• Fisiopatología de la hipertensión arterial pulmonar

  2017cites this paper
• Hypertension artérielle pulmonaire : approche pratique, psychologique et thérapeutique selon les recommandations européennes de 2015

  2017cites this paper
• Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS

  2017cites this paper
• Nouvelles approches diagnostiques et thérapeutiques dans l'hypertension pulmonaire : apport de la tomodensitométrie et identification du facteur de croissance des nerfs NGF comme nouvelle cible thérapeutique

  2016cites this paper
• The benefit of using a low dose calcium channel blocker in a patient with idiopathic pulmonary hypertension

  2016cites this paper
• Prediction of New Diagnostic and Therapeutic Approaches in Pulmonary Arterial Hypertension by Systems Biology Metho

  2016cites this paper
• Protective effect of Chinese sumac ( Rhus typhina L . ) fruit extract on angiotensin II-induced hypertension

  2016cites this paper
• Conjugated Alpha-Alumina nanoparticle with vasoactive intestinal peptide as a Nano-drug in treatment of allergic asthma in mice.

  2016cites this paper
• Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLADR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures

  2016cites this paper
• Right sided heart failure and pulmonary hypertension: New insights into disease mechanisms and treatment modalities ☆

  2016cites this paper
• Novel Strategies in the Treatment of Pulmonary Arterial Hypertension.

  2016cites this paper
• Future perspectives in pulmonary arterial hypertension

  2016cites this paper
• The modulation of smooth muscle contractility by specialised pro-resolving mediators

  2016cites this paper
• Zukunftsperspektiven auf dem Gebiet der pulmonal-arteriellen Hypertonie

  2016cites this paper
• Physiopathology of Pulmonary Hypertension: from Bio-Molecular Mechanism to Target Treatment

  2016cites this paper
• Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future.

  2016cites this paper
• Interventions for treating pulmonary hypertension in people with sickle cell disease or thalassaemia

  2015cites this paper
• Rôle de SIRT1 et de la biogenèse mitochondriale dans la prolifération des cellules du muscle lisse de l'artère pulmonaire

  2015cites this paper
• Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.

  2015cites this paper
• Pathogenic Mechanisms of Pulmonary Hypertension

  2015cites this paper
• Novel Targets of Drug Treatment for Pulmonary Hypertension

  2015cites this paper
• Inhaled Therapies for Pulmonary Hypertension

  2015cites this paper
• Aerosolized Medications for Gene and Peptide Therapy

  2015cites this paper
• Novel investigational therapies for treating pulmonary arterial hypertension

  2015cites this paper
• Pathways and Drugs in Pulmonary Arterial Hypertension – Focus on the Role of Endothelin Receptor Antagonists

  2015cites this paper
• Augmentation of the effects of vasoactive intestinal peptide aerosol on pulmonary hypertension via coapplication of a neutral endopeptidase 24.11 inhibitor.

  2015cites this paper
• Molecular Biological Aspects, Therapeutic Targets and New Treatment Strategies

  2015cites this paper
• Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats.

  2014cites this paper
• Targeted therapies in pulmonary arterial hypertension.

  2014cites this paper
• 2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

  2014cites this paper
• [New trial designs and potential therapies for pulmonary artery hypertension].

  2014cites this paper
• This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

  2014cites this paper
• ADMA metabolism and chronic hypoxia-induced pulmonary hypertenstion

  2014cites this paper
• Pulmonary arterial hypertension: yesterday, today, tomorrow.

  2014cites this paper
• The role of the osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the pathogenesis of pulmonary arterial hypertension.

  2014cites this paper
• Novel and emerging therapies for pulmonary hypertension.

  2014cites this paper
• Arterial Hypertension 2014 Guidelines of Taiwan Society of Cardiology ( TSOC ) for the Management of Pulmonary Arterial Hypertension

  2014cites this paper
• Molecular imaging of the pulmonary circulation in health and disease

  2014cites this paper